Growth hormone (GH) effects on skeletal development are well recognized. GH promotes longitudinal bone growth during childhood and attainment of adult bone mass [1, 2] . However, GH also plays a role in adult skeletal mass maintenance. Insulin-like growth factor 1 (IGF-1) influences development and function of several skeletal cell lineages. Independently of IGF-1, GH stimulates chondrocytes and osteoblasts; precursors of proliferation and differentiation. Simultaneously, bone resorption is mainly stimulated by IGF-1, whereas GH negatively modulates this effect by inducing the synthesis of osteoprotegerin by osteoblasts. Furthermore, GH may influence parathyroid hormone secretion pattern through phosphate retention, thus further influencing bone remodeling.
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Children and adults with GH deficiency (GHD) often have decreased bone mineral density (BMD) and bone mineral content (BMC), as measured by dual energy x-ray absorptiometry [3] [4] [5] [6] . Most likely, GHD severity influences the degree of bone loss. Several predictors of BMD response to GH replacement in adults have been described; baseline BMD, gender (men show better improvement than women in randomized and prospective studies), duration of treatment (>1 year), concomitant pituitary deficiencies, and severity of GHD [7] .
Fracture risk in patients with GHD is also high [8] ; patients with hypopituitarism and GHD have a 2-5 times increased fracture risk, which is dependent on baseline disease and multiple hormonal replacements. Of note, BMD, as in other patients with pituitary tumors (acromegaly, for example) might not be a good predictor of fracture risk [9] . A long-term (6-year) study [10] revealed a higher number of radiographic vertebral fractures in untreated compared with treated GHD patients, irrespective of age. Interestingly, in a large prospective database study of GHD patients [11] , those with osteoporosis had similar fracture rates either with or without GH replacement, but GH replacement prevented fractures only for patients without osteoporosis at baseline.
Despite BMD increase, the benefit of GH replacement on bone is not obvious in all GHD patients and an optimal GH dose to achieve the highest BMD increase remains unclear [8] ; some studies suggest no correlation between GH dose and BMD change [9] .
Over the last decade, GH has been US Food and Drug Administration approved for other adult indications, in addition to GHD, including human immunodeficiency virus associated cachexia and short bowel syndrome. Therefore, given an exponentially increasing number of patients living with osteoporosis, there is renewed interest in GH use to treat age-related bone loss.
Indeed, BMD in older women has been shown to be positively correlated with endogenous GH secretion and decreased IGF-1 has been associated with an increased risk of osteoporotic fractures [12] . Based on well-described GH actions on bone with improved BMD and expected IGF-1 decrease with age, many authors have hypothesized that GH administration could improve BMD in older osteoporotic adults, especially women, even in the absence of GHD per se.
Barake et al. [13] , conducted a systematic literature review and a meta-analysis to answer an important question; is GH beneficial in patients with age-related bone loss, by both increasing BMD, but more importantly by decreasing fracture risk, even in the absence of pituitary deficiencies (and documented GHD).
Over the years, GH and osteoporosis research has been scarce, with conflicting results. Notably, Barake et al. [13] contacted the corresponding authors of three studies with inconsistent data and fortunately were able to obtain additional data on two [14, 15] .
For their meta-analysis [13] , data were limited to seven randomized studies that included 272 post-menopausal women (61-69 years), treated with either GH or control (6-24 months), and an eighth extension trial. Complicating the analysis was that all women received concurrent osteoporosis therapies in all, but one study. Also many women had been treated with estrogen, including oral, which may have rendered GH treatment ineffective; women taking oral estrogen require higher doses (~30% higher) to achieve the same IGF-1 levels.
Barake et al. [13] combined results of three randomized trials and noted no significant difference with GH therapy on BMD (total hip, femoral neck or lumbar spine) or BMC when compared to placebo. Bone biomarkers increased, however the trend only reached statistical significance for carboxy-terminal propeptide of procollagen type I. It is not clear if the lack of a significant BMD change was related to the short duration of study GH therapy; patients were older and remodeling efficacy seems to decrease with aging. Conversely, based on four studies (short and long-term), a significant decrease in the risk of fracture, (RR = 0.63 [0.46, 0.87]) was observed overall with GH treatment. Notably, without the long-term study [16] . GH role in decreasing fracture risk would have been nonsignificant.
There is, however, a paucity of studies, that have addressed the effect of GH receptor exon 3 deletion polymorphism [7] in predicting skeletal fragility in hypopituitary adults with GHD and its potential implication on the response to GH replacement therapy. GHR polymorphism can partially explain the wide responses to GH in agerelated osteoporosis; any potential implication for pharmacogenetics needs further study.
The safety of GH treatment has been well described [9, 11] . Studies included by Barake et al. [13] , observed previously recognized fluid retention side effects (peripheral edema, myalgias, arthralgias, and carpal tunnel syndrome), however, frequency and severity of events were not systematically reported. When described, symptoms were usually transient and mostly relieved by decreasing the GH dose.
Largely, all studies reviewed in Barake et al. [13] , metaanalysis had significant design and follow-up caveats; these are well acknowledged. Overall, there were no major adverse events observed and mortality was not increased, but not all studies reported uniformly all side effects.
In conclusion, GH treatment in patients without documented GHD might indeed decrease fracture risk in some patients, especially in a subgroup of osteoporotic patients, with lower IGF-1 levels. Larger and long-term randomized studies are needed to elucidate the effects of a stable longterm regimen of GH treatment in both men and women with age-related osteoporosis on BMD, bone architecture and fracture risk either consecutive or concomitant to antiresorptive or anabolic treatment.
Currently, there is no evidence to recommend GH use for osteoporosis treatment and fracture prevention. Up-to-date prevention and treatment of osteoporosis guidelines in both men and women should be followed to decrease severe associated morbidity and mortality.
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